The International Society for Pharmacoeconomics and Outcomes Research on Monday announced the launch of its new website and association management system, the first phase of a comprehensive information technology initiative. "We are very pleased to launch phase 1 of this comprehensive IT […]
PharmaVOICE Honors ISPOR CEO Berg
PharmaVOICE magazine named Nancy Berg, CEO and executive director of the International Society for Pharmacoeconomics and Outcomes Research, a 2018 PharmaVOICE 100 honoree. Berg was honored as a "transformational leader" in the Commander and Chief rank. She became ISPOR's chief executive in 2014, […]
ISPOR Receives 2018 ‘Power of A’ Award
The International Society for Pharmacoeconomics and Outcomes Research announced July 9 it was honored with the American Society of Association Executives' (ASAE) 2018 "Power of A" Silver Award for Good Practices for Outcomes Research Reports. The honor, according to a press release, "sets […]
ISPOR: Value in Health Impact Factor Hits 5.494
The International Society for Pharmacoeconomics and Outcomes Research announced Thursday that its flagship journal, Value in Health, had hit an impact factor of 5.494 on new data from Clarivate Analytics' Journal Citation Reports. According to a press release, the increase marks the fifth straight […]
Value in Health Announces Study on Cost-Effectiveness Analyses, Cost
The International Society of Pharmacoeconomics and Outcomes Research's Value in Health earlier this week announced a new study focused on achieving "reasonable drug cost estimates for U.S.-based cost-effectiveness analyses." According to a press release, the report, "A Transparent and Consistent […]
ISPOR Seeking Comments on Trump’s Drug Pricing Blueprint
The International Society for Pharmacoeconomics and Outcomes Research is asking members to submit their feedback on the Health and Human Services' recent call for comments on the Trump administration's drug pricing blueprint. ISPOR says it would prefer members focus their comments on sections it […]
Center for Biosimilars Offers Key Biosimilars Takeaways from ISPOR 2018
The Center for Biosimilars recently offered seven key takeaways from the International Society for Pharmacoeconomics and Outcomes Research's Baltimore meeting. Researchers during the meeting said the U.S. could save roughly $38.3 million over three years if two infliximab biosimilars earn […]
Panelists Discuss Challenges of Measuring Value in High-Cost Drugs for Rare Diseases
As medicine continues to evolve and solutions for rare diseases come in greater frequency, so to does the way stakeholders address the costs associated and begin to think about value, according to a recent article in the American Journal of Managed Care (AJMC). Panelists at the 23rd annual […]
Panel: Cultural Shift Key in Personalized Medicine
A significant cultural shift may be needed to implement a more personalized approach to medicine in the U.S., according to an International Society for Pharmacoeconomics and Outcomes Research panel. The American Journal of Managed Care reports that the panel found a lack of economic and clinical […]
Panel Grapples with Value Assessments
A panel on Monday during ISPOR's 2018 meeting shined a spotlight on the role of value assessments in private payer coverage and formulary decision-making. Tufts Medical Center professor James Chambers, panel moderator, kicked off the discussion with an overview of how often payers cited health […]
